VimRx Pharmaceuticals
This article was originally published in The Gray Sheet
Executive Summary
Inks definitive agreement with Baxter Healthcare to acquire 100% ownership of Nexell Therapeutics. VimRx intends to unify its corporate structure with Nexell, assume the Nexell name, and relocate its headquarters to Irvine, California. In exchange for its Nexell securities, Baxter obtains 3 mil. shares of VimRx stock and other VimRx securities options. In January, Nexell's Isolex 300 stem cell selection system was found "approvable" by FDA, provided more information for labeling and inspection purposes is submitted